SLC5A2 and chronic kidney disease: Additionally, for SGLT2 inhibitors and incretin-based therapies, evidence emerging from the post hoc analysis of secondary endpoints in patients with type 2 DM without baseline CKD further supports the concept that the kidney benefits of targeting glomerular hyperfiltration may extend to people without CKD but at high risk of CKD, i.e. they support the concept that glomerular hyperfiltration may be a therapeutic target in the prevention of CKD [36].